Immunogenicity, Vaccine

"Immunogenicity, Vaccine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

The capacity of VACCINES to stimulate the ADAPTIVE IMMUNE RESPONSE to produce antibodies and antigen-specific T-CELL responses.

Descriptor ID	D000071497
MeSH Number(s)	G12.070.500 G12.450.050.370.500 G12.450.050.460 G12.513
Concept/Terms	Immunogenicity, Vaccine Immunogenicity, Vaccine Vaccine Immunogenicity Antigenicity, Vaccine Vaccine Antigenicity

Below are MeSH descriptors whose meaning is more general than "Immunogenicity, Vaccine".

Biological Sciences [G]
Immune System Phenomena [G12]
Antibody Formation [G12.070]
Immunogenicity, Vaccine [G12.070.500]
Immunity [G12.450]
Adaptive Immunity [G12.450.050]
Immunity, Active [G12.450.050.370]
Immunogenicity, Vaccine [G12.450.050.370.500]
Immunogenicity, Vaccine [G12.450.050.460]
Immunogenicity, Vaccine [G12.513]

Below are MeSH descriptors whose meaning is related to "Immunogenicity, Vaccine".

Below are MeSH descriptors whose meaning is more specific than "Immunogenicity, Vaccine".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Immunogenicity, Vaccine" by people in this website by year, and whether "Immunogenicity, Vaccine" was a major or minor topic of these publications.

Bar chart showing 8 publications over 6 distinct years, with a maximum of 2 publications in 2020 and 2021

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2014	1	0	1
2017	1	0	1
2019	0	1	1
2020	1	1	2
2021	1	1	2
2022	0	1	1

Below are the most recent publications written about "Immunogenicity, Vaccine" by people in Profiles.

Haque A, Pant AB. Mitigating Covid-19 in the face of emerging virus variants, breakthrough infections and vaccine hesitancy. J Autoimmun. 2022 02; 127:102792.

View in: PubMed
Zeng C, Evans JP, Chakravarthy K, Qu P, Reisinger S, Song NJ, Rubinstein MP, Shields PG, Li Z, Liu SL. COVID-19 mRNA booster vaccines elicit strong protection against SARS-CoV-2 Omicron variant in patients with cancer. Cancer Cell. 2022 02 14; 40(2):117-119.

View in: PubMed
Wang J, Hou Z, Liu J, Gu Y, Wu Y, Chen Z, Ji J, Diao S, Qiu Y, Zou S, Zhang A, Zhang N, Wang F, Li X, Wang Y, Liu X, Lv C, Chen S, Liu D, Ji X, Liu C, Ren T, Sun J, Zhao Z, Wu F, Li F, Wang R, Yan Y, Zhang S, Ge G, Shao J, Yang S, Liu C, Huang Y, Xu D, Li X, Ai J, He Q, Zheng MH, Zhang L, Xie Q, Rockey DC, Fallowfield JA, Zhang W, Qi X. Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): A multicenter study. J Hepatol. 2021 08; 75(2):439-441.

View in: PubMed
Swamy GK, Metz TD, Edwards KM, Soper DE, Beigi RH, Campbell JD, Grassano L, Buffi G, Dreisbach A, Margarit I, Karsten A, Henry O, Lattanzi M, Bebia Z. Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in pregnant women and their infants: Results from a randomized placebo-controlled phase II trial. Vaccine. 2020 10 14; 38(44):6930-6940.

View in: PubMed
Platt HL, Greenberg D, Tapiero B, Clifford RA, Klein NP, Hurley DC, Shekar T, Li J, Hurtado K, Su SC, Nolan KM, Acosta CJ, McFetridge RD, Bickham K, Musey LK. A Phase II Trial of Safety, Tolerability and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Compared With 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants. Pediatr Infect Dis J. 2020 08; 39(8):763-770.

View in: PubMed
Federizon J, Frye A, Huang WC, Hart TM, He X, Beltran C, Marcinkiewicz AL, Mainprize IL, Wills MKB, Lin YP, Lovell JF. Immunogenicity of the Lyme disease antigen OspA, particleized by cobalt porphyrin-phospholipid liposomes. Vaccine. 2020 01 22; 38(4):942-950.

View in: PubMed
Misurac JM, VanDeVoorde RG, Kallash M, Iorember FM, Luckritz KE, Rheault MN, Jetton JG, Turman MA, Kapur G, Twombley KE, Hashmat S, Weaver DJ, Leiser JD, Nailescu C. Immunogenicity of Augmented Compared With Standard Dose Hepatitis B Vaccine in Pediatric Patients on Dialysis: a Midwest Pediatric Nephrology Consortium Study. Clin J Am Soc Nephrol. 2017 May 08; 12(5):772-778.

View in: PubMed
Halasa NB, Gerber MA, Berry AA, Anderson EL, Winokur P, Keyserling H, Eckard AR, Hill H, Wolff MC, McNeal MM, Edwards KM, Bernstein DI. Safety and Immunogenicity of Full-Dose Trivalent Inactivated Influenza Vaccine (TIV) Compared With Half-Dose TIV Administered to Children 6 Through 35 Months of Age. J Pediatric Infect Dis Soc. 2015 Sep; 4(3):214-24.

View in: PubMed

People

Explore

Similar Concepts

Top Journals